Kornimate/medical-research-clean huggingface dataset:
mobilization with movement vs. neural mobilization on nerve root function in patients with cervical radiculopathy

Conditions: Disc Herniation; Cervical Radiculopathy; Cervical Radiculopathy at C5 Nerve Root; Cervical Radiculopathy at C6 Nerve Root; Cervical Radiculopathy at C7 Nerve Root

Summary: this study will be conducted to compare the effect of sustained natural apophyseal glides (snags) versus neural mobilization on clinical outcomes such as 1- nerve root function in the form of: (a) peak to peak amplitude; (b) latency; (c) f wave. 2- pain pressure threshold (ppt) and 3- neck disability index (ndi) in patients with cervical disc (c5-c6 and/or c6-c7) herniation. seventy two patients from both gender with cervical disc (c 5-c 6 and/or c 6- c7) herniation with both sensory and motor nerve affections will be recruited for this study following referral from an experienced neurologist and confirmed diagnosis by mri. the patients' age will range between 20-50 years, body mass index (bmi) from 18 to 25 kg/cm2. the patients will be assigned randomly by permuted block to three equal groups; group (a) will receive snags in addition to traditional therapy, group (b) will receive neural mobilization in addition to traditional therapy and group (c) will receive traditional therapy. peak to peak amplitude, nerve latency and f wave will be measured by electromyography, , pressure pain threshold will be measured by commander algometer. neck disability will be measured by arabic neck disability index.


Eligibility criteria:
inclusion criteria: 1. seventy patients with cervical disc (c 5-c 6 and/or c 6- c7) herniation with both sensory and motor nerve affections, referred from neurologist and confirmed diagnosis by mri 2. both sexes. 3. age between 20-50 years. 4. patients with neck pain radiating down to the arm. 5. patients with positive findings for spurling test, upper limb tension test one (ultto), cervical distraction test and cervical rotation test towards the symptomatic side \<60. 6. bmi from 18 to 25 kg/cm2 7. existed active trigger points within middle trapezius and/ or cervical region. 8. positive pittsburgh sleep quality index' value \>10, means moderate and/ or sever difficulty. exclusion criteria: 1. patients experiencing primary shoulder or upper extremity problem of local origin 2. cardiovascular disorders and respiratory disorders, 3. pathological conditions involving cervical spine like vertebro basilar insufficiency and canal stenosis 4. osteophytes in cervical vertebrae 5. patients who were undergoing treatment for neck pain with other means of physiotherapy at the time of the study 6. cervical fractures, spinal surgery or other spinal pathologies (i.e. ankylosing spondylitis, spondylolisthesis) 7. peripheral nerve lesions like neurotmesis and axonotmesis.
drug repurposing for the prevention of chemotherapy-induced peripheral neuropathy (cipn)

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: chemotherapy cause many adverse events including induction of peripheral neuropathy. metformin, the ampk activator, was found to have protective effect against chemotherapy induced peripheral neuropathy in mouse model and in clinical trials as well. there are different hypothesized mechanisms through which metformin does the protective effect. such as enhancing mitochondrial activity, reduction of ros and nitric oxide and activation of ampk.

chemotherapy can cause a variety of side effects. one of the most common side effects is chemotherapy induced peripheral neuropathy (cipn), it commonly caused by paclitaxel chemotherapy which is usually used in the treatment of breast cancer. metformin which is known as a safe anti-diabetic drug, was found to have a protective effect on neurons. it gave positive results in chemotherapy induced peripheral neuropathy in mouse models and in some clinical trials

Eligibility criteria:
inclusion criteria: * age (18-75) male and female patients * scheduled to be treated with single agent paclitaxel * performance status according to eastern cooperative oncology group (ecog) \< 2. * patients who are willing and able to review and provide written consent, patients who can read the questionnaires exclusion criteria: * previous exposure to chemotherapy drugs that cause neuropathy, patients treated with medications that increase the risk of neuropathy like amiodarone, colchicine, metronidazole, phenytoin. * patients with impaired liver functions or kidney functions. * patients with a history of any serious adverse events or interaction or hypersensitivity to metformin. * pregnant or lactating females. * patients who are using metformin for any other cause. * patients with sensory or motor neuropathy of any grade prior to enrollment.

Keywords: cancer chemotherapy-induced peripheral neuropathy metformin neuropathy
a study of the safety and pharmacokinetics of ags-8m4 given in combination with chemotherapy in women with ovarian cancer

Conditions: Carcinoma; Ovarian Cancer; Ovarian Diseases; Ovarian Neoplasms

Summary: this is a parallel arm study to evaluate ags-8m4 administered in combination with chemotherapy in subjects with ovarian cancer. ags-8m4 will be administered as an iv infusion until disease worsens.

all subjects will receive ags-8m4 treatment. subjects will be enrolled into 1 of 2 treatment arms according to their disease status. a disease assessment will be performed every 8 or 9 weeks (± 3 days) depending on the treatment arm assignment. the assessment will be based both on changes in clinical symptoms, and radiographic images. subjects without evidence of disease progression may continue to receive treatment based on their original treatment assignment until disease progression or intolerability. a safety follow-up visit will occur 4 weeks after the last dose infusion of ags-8m4.

Eligibility criteria:
inclusion criteria: * subjects with recurrent disease stage iii/iv diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma * subjects with either platinum resistant or platinum sensitive ovarian cancer * at least 14 days of previous cytotoxic chemotherapy and have recovered from all toxicities * left ventricular ejection fraction (lvef) equal to or greater than the institutional lower limit of normal as measured by echocardiogram or muga (only required for platinum resistant patients) exclusion criteria: * active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of screening * use of any investigational drug within 30 days prior to screening * prior monoclonal antibody therapy other than avastin * avastin administration within 90 days of screening * history of thromboembolic events and bleeding disorders ≤ 3 months (e.g.,dvt or pe)

Keywords: clinical trial, phase1 combination drug therapy pharmacokinetics safety ovarian
phentermine/gastric band weight loss study

Conditions: Obesity

Summary: this is a prospective, randomized, double-blind controlled trial. the goal is to show whether the administration of daily oral phentermine will augment patient weight loss and resolve obesity associated comorbidities following gastric band operation.


Eligibility criteria:
inclusion criteria: * adult age 18-65 * bmi 35-55 * approved for gastric band operation exclusion criteria: * a known allergy to phentermine * take medications for attention deficit disorder (add) * monoamine oxidase inhibitors (maoi)for depression * selective serotonin reuptake inhibitor (ssris)for depression * history of heart problems (congested heart failure, coronary artery disease,cardiac stents, cardiac arrhythmias * hyperthyroidism * glaucoma * psychosis * history of drug abuse * uncontrolled hypertension (diastolic \>85)
effectiveness evaluation of three strategies of promotion of healthy dietary and physical activity behaviours to prevent weight excess among teenagers

Conditions: Body Weight; Nutrition Processes; Prevention

Summary: the aim of this study is to compare the effectiveness of three public health intervention strategies to reduce weight excess and obesity prevalence among teenagers within the frame of a public health program aiming at promoting healthy eating and physical activity behaviors.

a cluster randomised trial implemented in 24 high and technical schools including 20 000 fifth-former aims, on a three-year period, at evaluating the effectiveness of three strategies, combined or not, according a 2\*2\*2 factorial plan, concerning the promotion of healthy dietary and physical activity behaviours: to develop individual skills by individual and collective education, to propose favourable environment, to screen and care for subjects at risk of weight excess. main outcomes are improvement of knowledge, attitudes and behaviours, mean body mass index (bmi) change, proportion of obese children according to international standards after two years of follow-up, and finally psychological and sociological factors which are facilitators or barriers to such actions. the evidence of the effectiveness of one or the other of the strategies will help to define interventions framework for medical, educative and economic sector actors.

Eligibility criteria:
inclusion criteria: * being student in the included public high school in region of lorraine (east of france) whatever the age exclusion criteria: * none

Keywords: obesity nutrition cluster randomized trial high school primary prevention
lottery incentives for moving

Conditions: Obesity; Sedentary Lifestyle

Summary: the purpose of the study is to learn more about effective ways to motivate people to increase their non-exercise energy expenditure exercise. this is an important research question because obesity and weight-related issues are increasingly becoming a problem in america. this project will address this research question by testing the effect of two different incentive schemes in motivating employees who are predominantly sedentary to use walkstations at work. the walkstations are treadmills that move at a very slow rate (maximum 2miles / hour) and are attached to a work station (i.e. with computer and telephone); they therefore are designed to increase energy spent not through heavy exercise, but through small changes in posture and movement associated with routines in daily life (called nonexercise activity thermogenesis or neat). subjects will be employees of blue cross blue shield of massachusetts (bcbsma). subjects will be the control participants from the previous walkstation study we ran with bcbsma. all 120 control participants from this previous study will be told that they can now participate in a study that involves the walkstations (up until now, they have not been given access to the walkstations). these participants from the previous study will be sent an email informing them that they are eligible to participate in this new walkstation pilot. those who are interested in participating will then be invited to sign up for an enrollment session. there will be no incentives for participating in the initial enrollment session. for the 2 month follow-up session, participants will have a chance to win 1 of 3 prizes (1 \* $100, 2 \* $50) for completing the follow-up.


Eligibility criteria:
inclusion criteria: * must pass parq exclusion criteria: * if fail parq
omentin-1 level in psoriatic patients treated with narrowband ultraviolet b phototherapy versus acitretin

Conditions: Psoriasis

Summary: studying the effects of narrowband ultraviolet b versus acitretin on psoriatic patients

compare the effects of narrowband ultraviolet b versus acitretin on serum omentin-1 level in psoriatic patients as case control study by dividing patients into 3 groups: group 1 include patients receive narrowband ultraviolet b, group ii includes patients receive acitretin (0.5-1 mg/day) and control group. the duration of this study about 3 months after receving those interventions.

Eligibility criteria:
inclusion criteria: * patients of both sexes with psoriasis vulgaris. exclusion criteria: * • patients with history of malignancies, renal and liver diseases. * patients received nb-uvb phototherapy in the last 6 months. * patients treated with methotrexate or biologic agents and any systemic treatment of psoriasis.
study of an expandable interbody device for the lumbar spine

Conditions: Degenerative Disc Disease

Summary: the primary objective of this study is to evaluate the safety and efficacy of caliber expandable spacer for the treatment of degenerative disc disease. radiographic outcomes, intra-operative parameters, clinical outcomes, and patient satisfaction will be obtained from patients in this 2 year follow-up clinical study.

patients will be followed-up at 3weeks, 6 weeks, 3 months, 6 months, 12 and 24 months with x-rays and questionnaires to determine their satisfaction, healing, fusion and return to work status

Eligibility criteria:
inclusion criteria: * ddd at 1 or 2 levels between l2 and s1 * between 18 and 80 years of age * unresponsiveness to documented non-surgical treatment modalities for a minimum of six months * ability to provide a signed informed consent exclusion criteria: * trauma at level(s) to be fused * previous documentation of osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated * immunosuppressive disorder * history of substance abuse * any known allergy to a metal alloy
clinical utility of an age, sex, and gene expression score (asges or corus cad) in african american patients.

Conditions: Coronary Artery Disease; Angina Pectoris; Chest Pain; Cardiovascular Diseases; Coronary Heart Disease; CHD; CVD; CAD

Summary: this is a retrospective study, designed to be conducted at a single-center in the us. the study will conduct a one-time data abstraction from approximately 500 patient medical charts who received age/sex/gene expression score (asges) also knows as corus cad testing, by order of the principal investigator. limited demographic data and patient data pertaining to cardiology referral or advanced diagnostic testing will be collected. all data will be collected anonymously.

though the diagnostic properties of age/sex/gene expression score (asges) or corus cad have been evaluated in previous observational studies, there are limited data regarding how primary care clinicians are using the results of the test in the care and management of patients with symptoms suggestive of angina in the african-america patient population. this retrospective study is designed to examine the relationship between the corus cad (asges) score and patterns of care regarding cardiology referral or further cardiac diagnostic testing in an african-american patient population single-center site. this is a retrospective study, designed to be conducted at a single-center in the us. the study will conduct a one-time data abstraction from approximately 500 patient medical charts who received corus cad (asges) testing, by order of the principal investigator. limited demographic data and patient data pertaining to cardiology referral or advanced diagnostic testing will be collected. all data will be collected anonymously. irb approval will be requested with a waiver of informed consent, as no identifying information will be collected. this retrospective study is designed to understand the patterns of care, including referrals for cardiac care and testing (including referrals to a cardiologist, exercise stress testing, cardiac computerized tomography angiography (ccta), invasive cardiac angiography (ica)) within an african-american patient population.

Eligibility criteria:
inclusion criteria: * all patients receiving corus cad (asges) from 2008-2012. exclusion criteria: * if any of the following co-moribidities, medical conditions, or current medical statuses are noted in the patient medical chart, s/he will be excluded from the analysis dataset: 1. history of diabetes; 2. revascularization or myocardial infarction; 3. systemic infection or inflammatory condition; or 4. use of steroids, immunosuppressive agents, or chemotherapeutic agents.

Keywords: corus cad personalized medicine cad asges age/sex/gene expression score ges cvd chd precision medicine clinical utility gene expression coronary heart disease cardiovascular disease chest pain coronary artery disease angina pectoris exercise stress testing ct angiography invasive cardiac angiography african-american patient ica cta
kinematical evaluation of lumbar rotation in chronic low back pain

Conditions: Low Back Pain

Summary: low back pain (lbp) is considered one of the most common musculoskeletal disorders in modern society, resulting in substantial costs to society. factors associated with the development of low back pain include poor posture, strenuous work with the body, inadequate non ergonomic work and traumas. rotation movement pattern of the lumbar spine in different positions is essential aspect in understanding the lbp pathophysiology. rotation coupled with forward bending (flexion) is a dominant factor which could increase the risk lbp and disc prolapse. there is also a decline in range of motion (rom) of rotation in forward bending (flexion) compared to neutral position during sitting and standing. in addition,lumbar rotation movement patterns differ in population with lbp compared to asymptomatic individuals. healthy individuals exhibit rotation accompanied by consistent coupled movement patterns of lateral bending in the opposite direction at thr upper levels, and by lateral bending in tge same direction at the lower levels . while chronic lbp patients exhibit non consistent patterns altered from those of the normal population.

according to the investigators, kinematic measures of velocity and acceleration of lumbar rotation in neutral position and full flexion in sitting and standing did not studied yet. evaluating these parameters, in addition to rom and plains evaluation in the lbp population, compared to healthy population will contribute a lot in understanding this issue.

Eligibility criteria:
inclusion criteria: * non specific chronic lbp (three months or more) * insured by clalit health care services * signed informed consent exclusion criteria: * history of spinal /pelvic surgery. * trauma or fracture of spine /pelvis. * inflammatory diseases of spine. * radiation to lower extremities . * neurological disease. * malignancy disease. structural deformity of vertebral structures(scoliosis, kyphosis).

Keywords: low back pain disability kinematic measures
postoperative analgesia after cesarean section; comparison among ultrasound guided erector spinae, quadratus lumborum or transversus abdominis plane blocks

Conditions: Postoperative Analgesia; Cesarean Section; Erector Spinae Block; Quadratus Lumborum Block; Transversus Abdominis Plane Block

Summary: the aim of this prospective randomized controlled study is to compare the analgesic efficacy of the ultrasound-guided erector spinae plane block, ultrasound-guided quadratus lumborum plane block, and ultrasound-guided transversus abdominis plane block in patients undergoing elective cesarean section.

acute postpartum pain is a key determinant of maternal satisfaction; may lead to persistent postoperative pain. opioids are used to control severe pain. however, they have many common side effects as sedation, dizziness, nausea, vomiting, constipation, physical dependence, tolerance, and respiratory depression. transversus abdominis plane (tap) block is a regional injection of local anesthetic between the transversus abdominis and internal oblique muscle planes. tap block affects the sensory nerves of the anterolateral abdominal wall (t6-l1) that innervate the abdomen. tap block is an easy technique, and decreases postoperative pain and opioid consumption. erector spinae plane block (espb), first described for analgesia in thoracic neuropathic pain has also been reported for the management of other causes of acute postoperative pain. quadratus lumborum block (qlb) differ from the transversus abdominis plane block (tap) it is a block of the posterior abdominal wall. it is also referred to as an inter fascial plane block because it requires the injection of a local anesthetic into the thoracolumbar fascia (tlf).

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * american society of anesthesiologists (asa) classification ii. * female patients scheduled for elective cesarean section under spinal anesthesia. exclusion criteria: * patient refusal. * patients who are taking analgesics for chronic illness or have history of substance abuse. * patients who are unable to describe their postoperative pain (e.g., language barrier or neuropsychiatric disorder). * patients with a history of coagulopathy. * patients weight less than 60 kilograms. * patient height less than 150 cm. * patients with known local anesthetics and opioid allergy. * patients with infection at the site of the needle puncture. * patients with major respiratory, cardiac, renal, or hepatic disorders.
a checklist (advanced care planning) for the assessment of mobility needs in patients with sarcoma

Conditions: Metastatic Sarcoma; Sarcoma

Summary: this trial tests how well the advanced care planning around mobility needs checklist tool works to assess future mobility needs in patients with sarcoma. gathering information about sarcoma patients that have had surgery to either save or remove a limb may help doctors learn more about a patient's mobility needs. using an advance care planning mobility needs assessment may help improve the quality of life in patients with sarcoma by helping them plan for their future mobility needs.

outline: field test: participants complete the advance care planning (acp) mobility checklist on study. participants complete questionnaires at baseline and after completing the checklist intervention and undergo interview on study. participants' medical records are also reviewed.

Eligibility criteria:
inclusion criteria: * patients: age 18 years of age or older. * patients: english speaking * patients: able to provide informed consent * patients: have access to a computer or other device to fill out the online checklist * patients: have had either limb salvage or amputation surgery for sarcoma within the last 6 months or have metastatic (stage iv) sarcoma and are in active treatment. * caregivers: age 18 years of age or older * caregivers: english speaking * caregivers: able to provide informed consent * caregivers: have access to a computer or other device to fill out the online checklist * caregivers: the person (family member or friend) whom the patient indicates being an informal caregiver